Improving Drug Development Programs with Novel Epigenomic Insights
- A deep dive into epigenomic biomarkers within the precision oncology toolkit, and how methylation-based signatures reveal tumour biology beyond genomics
- An overview of emerging data demonstrating where epigenomic biomarkers deliver the greatest impact for patient stratification and trial enrichment
- A discussion of Guardant Health’s expanding global testing capabilities and their role in advancing epigenomics in clinical care